Managing Angina Without Surgery
Thursday, September 11th, 2008Blockages in the heart’s arteries commonly cause chest pains called angina. Cardiologists possess ever-improving invasive tools for restoring blood flow, including angioplasty (blowing up balloons to expand the artery at sites of plaque), stenting (insertion of cylindrical props of metal mesh), and bypass surgery, increasingly through very small incisions.
But while these invasive treatments decisively relieve symptoms in most patients, they actually prevent heart attacks and deaths only in special circumstances — notably, when patients are treated within a few hours of an acute heart attack. At the same time, we now have several effective classes of drugs that reduce the heart’s workload, improve blood flow by dilating arteries, and increasingly target the diseased artery itself.
So the question that patients and their physicians now confront is when to turn to the invasive strategies that have long been a mainstay of angina management. A recent analysis of data from pivotal clinical trial called COURAGE provides some important new insights.
In this study, over 2,000 patients with stable angina were randomized into groups receiving aggressive drug therapy with or without additional angioplasty and stenting. The primary results, published in 2007, showed no additional benefit to invasive treatments with regard to heart attack or deaths in the group during 4.6 years of follow-up.
The new data, published last month in The New England Journal of Medicine, addressed whether adding invasive treatment to intense medical treatment reduced the frequency of angina and improved quality of life and well-being in these patients.
Shortly after treatment, the patients who had had invasive revascularization reported slightly less angina and slightly better quality of life. But by the end of the 4.6 years of follow-up, the patients who did not receive invasive treatments were faring as well as those who did (although about one-fifth of those originally treated without surgery ultimately required mechanical revascularization).
This study teaches us two remarkable lessons. First, starting aggressive therapy, be it with drugs or drugs plus revascularization, improved symptoms and quality of life in both groups — promptly in the case of surgical revascularization, but rapidly even for drug therapy alone. This is extremely good news for patients with angina: modern therapy is quick, effective and results in an excellent quality of life in most individuals.
The surprising and progressive benefit of non-invasive therapy may come about because some of the newer drugs favorably alter the biology of the artery and plaque (notably statins and agents that interrupt the action of the hormone angiotensin). Statins lower “bad cholesterol” (LDL), one of the drivers of atherosclerosis, and also appear to calm inflammation in the plaque independent of effects on LDL. Blocking angiotensin action may also provide a benefit to arterial health beyond just lowering blood pressure.
The second message: we don’t need to rush into surgery as a first step in people with stable angina. We can apply aggressive lifestyle and drug therapy, and turn to invasive strategies if these non-invasive measures don’t do the trick. These new data, in the context of many other studies, allow us to take a staged approach to the management of stable angina with confidence that we do not jeopardize longevity or increase risk of heart attacks.
Source — The New York Times
